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Background. The kinetics of hepatitis B surface antigen (HBsAg) are predictive in HBV-infected patients treated with pegylated interferon. Knowledge about the value of HBsAg levels in patients coinfected with HBV and human immunodeficiency virus (HIV) is lacking.
Methods. We quantified serum HBsAg in a Dutch multicenter cohort of 104 patients coinfected with HIV and HBV who were treated with tenofovir disoproxil fumarate (TDF) as part of highly active antiretroviral therapy. The median duration of therapy was 57 months (interquartile range, 34-72 months).
Results. Hepatitis B e antigen (HBeAg)-positive patients achieved a decline of 2.2 log IU/mL in HBsAg, whereas HBeAg-negative patients only achieved a decline of 0.6 log IU/mL during 6 years of TDF therapy. Declines in HBsAg at months 6 and 12 correlated with CD4 cell count for HBeAg-positive patients. Five HBeAgpositive patients (8%) and 3 HBeAg-negative patients (8%) cleared HBsAg. HBeAg-negative patients who cleared HBsAg had lower baseline HBsAg as compared to patients who remained HBsAg positive. The majority of patients who cleared HBsAg achieved this end point within the first year. In HBeAg-positive patients, decline in HBsAg at month 6 was predictive of achieving HBsAg seroclearance.
Conclusions. Receipt of TDF therapy by HIV/HBV-coinfected patients for up to 6 years led to a significant decrease in HBsAg in the HBeAg-positive population. HBsAg kinetics early during treatment were predictive of HBsAg seroclearance and correlated with an increased CD4 cell count, underlining the importance of immune restoration in HBV clearance.
Tenofovir disoproxil fumarate (TDF) is a potent inhibitor of both hepatitis B virus (HBV) and human immunodeficiency virus (HIV) [1] [2] . The first data on the antiviral efficacy of TDF against HBV were derived from studies involving HIV/HBV-coinfected patients [3] [4] [5] , and its efficacy was subsequently demonstrated in a large randomized trial [6] . Unfortunately, serum hepatitis B surface antigen (HBsAg) seroclearance, the outcome closest to clinical cure of the disease, remains a rare event during long-term HBV therapy with potent nucleos(t)ide analogues (NAs), especially among Hepatitis B e antigen (HBeAg)-negative patients [2, 7] .
Quantification of HBsAg level was recently correlated with intrahepatic markers of HBV, such as covalently closed circular DNA and intrahepatic HBV DNA level [8] [9] [10] . Moreover, HBsAg quantification has proven its value in predicting response for HBV-monoinfected patients treated with pegylated interferon [11] [12] [13] [14] . In contrast, data on the kinetics of HBsAg in NA-treated patients with HBV is limited so far, and the clinical use of these measurement has not been proven [15] [16] [17] [18] .
Despite effective suppression of viral replication by current highly active antiretroviral therapy (HAART), patients infected with both HIV and HBV have a higher risk of progression to cirrhosis and its complications, compared with HIVmonoinfected patients [19] [20] . Clearance of HBV in these coinfected patients could therefore be of vital importance for their long-term prognosis.
Knowledge of the kinetics of serum HBsAg and its predictive value during long-term potent suppression by TDF in HIV/HBV-coinfected patients is limited but may help to identify patients who are likely to clear HBsAg [21] . Recently, we presented data on the long-term efficacy and safety of up to 5 years of TDF-based therapy in HIV/HBV-coinfected patients from a Dutch multicenter cohort study [22] . In the current study, we use this cohort to investigate long-term serum HBsAg level kinetics in HIV/HBV-coinfected patients treated with TDF, to identify factors at baseline and during treatment that are associated with decreased HBsAg level and seroclearance of HBsAg, and to use decreases in HBsAg level during treatment to predict the duration of treatment required to achieve clearance of HBsAg.
MATERIALS AND METHODS

Study Population
All consecutive HIV/HBV-coinfected patients treated with TDF at 5 Dutch centers specializing in viral hepatitis and HIV management were included. Patients were eligible for this study if they were HBsAg positive for at least 6 months, were anti-HIV positive at baseline, and were treated with TDF as a part of a HAART regimen for at least 6 months. Patients were excluded if they had hepatitis C virus or hepatitis delta virus coinfection or were receiving concomitant pegylated interferon therapy. The study was conducted in accordance with the guidelines of the Declaration of Helsinki and the principles of Good Clinical Practice. Patients gave written informed consent according to standards of the local ethics committees. Diagnosis of cirrhosis at baseline was based on the following criteria: histological confirmation and/or clear signs on an abdominal ultrasonogram indicative of cirrhosis (ie, spleen size >12 cm; portal vein >16 mm; or nodules within the hepatic parenchyma).
Laboratory Tests
Serum alanine aminotransferase (ALT) levels were measured using automated techniques and are expressed as values representing a ratio to the upper limit of the normal range (ULN). Absolute numbers of CD4 T lymphocytes were assessed on whole blood by flow cytometry. Detection of HBeAg and antibody against HBeAg (anti-HBe) was performed using commercially available enzyme immunoassays. HBV genotype was determined at baseline by direct sequencing or by using the INNO-LiPA assay (Innogenetics, Gent, Belgium). Serum HBsAg level was quantified in stored samples at baseline, at 6 months, and at yearly intervals thereafter, using the ARCHI-TECT HBsAg assay (Abbott Laboratories; range, 0.05-250 IU/mL). Serum HBV DNA levels were measured using the Cobas TaqMan polymerase chain reaction assays (Roche; lower limit of detection, 20 IU/mL). HIV RNA level was assessed quantitatively with the Cobas Ampliprep/Cobas Amplicor assay, version 1.5 (Roche Molecular Systems; lower limit of detection, 50 copies/mL).
Statistical Analysis
Serum HBsAg, HBV DNA, and HIV RNA levels were logarithmically transformed for analysis. Continuous variables are presented as mean (±SD) or median (interquartile range [IQR] ), where appropriate. Continuous variables were compared using the t test or the Mann-Whitney U test. Categorical variables were compared using the χ 2 or Fisher exact test. The decline of the serum HBsAg level from baseline was analyzed with a repeated mixed regression model with a heterogeneous compound symmetry structure of the covariance matrix. The patient-specific durations of treatment required to achieve a 1-log decrease in the HBsAg and HBsAg levels were estimated by applying a linear mixed regression model with a random slope and random intercept to the observed HBsAg levels at the exact visit times. Statistical analyses were performed using SPSS, version 15.0 (SPSS, Chicago, IL) and SAS, version 9.2 (SAS Institute, Cary, NC). All statistical tests were 2-sided and were evaluated at the 0.05 level of significance.
RESULTS
A total of 104 patients were included in this analysis. Baseline characteristics of the study population are presented in Table 1 . Patients were predominantly male and white and mostly harbored HBV genotype A. Baseline HBV DNA and HBsAg levels were higher in HBeAg-positive patients, compared with HBeAg-negative patients, and were strongly correlated within the HBeAg-positive population (r = 0.62; P < .001). The baseline HBsAg level showed a moderate correlation with ALT level (r = 0.38; P = .02) in HBeAg-negative patients. Among HBeAg-positive patients, the baseline HBsAg level was higher in those infected with HBV genotype A than in those with non-genotype A infection (4.9 vs 4.2 log IU/mL; P = .02); for HBeAg-negative patients, this difference was not significant (3.2 vs 2.9 log IU/mL; P = .65). The median duration of follow-up of the study population was 57 months (IQR, 34-72 months).
Decline in HBsAg During Treatment
HBsAg, HBV DNA, and CD4 cell count kinetics for a treatment period of up to 6 years are depicted in Figure 1 . The decline in HBsAg level at year 1 was 1.2 log IU/mL (P < .001, compared with baseline) for HBeAg-positive patients and only 0.2 log IU/mL (P = .58) for HBeAg-negative patients. The decline in HBsAg level at year 6 of therapy was 2.2 log IU/mL for HBeAg-positive patients (P < .001) and 0.6 log IU/mL for HBeAg-negative patients (P = .07). Within the HBeAg-positive population, 68% of patients achieved at least a 1-log decline in the HBsAg level, compared with only 16% of HBeAg-negative patients. HBV DNA and HBsAg levels were significantly correlated during follow-up (r > 0.60). We investigated associations between baseline variables and HBsAg level kinetics in HBeAg-positive and HBeAg-negative patients separately. By use of univariate analysis, a more pronounced decline in HBsAg was found in HBeAg-positive patients with either genotype A (P = .08, compared with nongenotype A), no previous lamivudine exposure (P = .03), a higher baseline HBsAg level (P < .001), and a higher HBV DNA level (P = .03). In multivariate analysis, only a higher HBsAg level remained significant (P = .02); in contrast, HBV genotype A (P = .58), previous lamivudine exposure (P = .58), and a higher HBV DNA level (P = .42) did not remain significantly associated with decline in HBsAg level. For HBeAg-negative patients, no significant baseline predictors of HBsAg kinetics could be identified.
The CD4 cell count increased steadily during TDF therapy for both HBeAg-positive and HBeAg-negative patients, with the largest increase (±SD) in the first 6 months (129 ± 155 cells/mm 3 for HBeAg-positive patients and 87 ± 138 cells/ mm 3 for HBeAg-negative patients; Figure 1 ). A decline in
HBsAg was correlated with an increase in CD4 cell count in HBeAg-positive patients early during treatment, at month 6 (r = 0.34; P = .04) and month 12 (r = 0.33; P = .03). In 3 of 4 HBeAg-positive patients achieving clearance of HBsAg within the first year, this was accompanied by an increase in CD4 cell count of >150 cells/mm 3 .
Kinetics of HBsAg in Relation to HBeAg and HBsAg Serological Response
HBeAg-Positive Patients
The HBeAg-positive population comprised 66 patients, of whom 24 (36%) achieved HBeAg loss and 12 (18%) achieved HBeAg seroconversion. Kaplan-Meier estimates of HBeAg loss and HBeAg seroconversion were 17% and 8%, respectively, at year 1, increasing to 47% and 24%, respectively, at year 6 ( Figure 2A) . The baseline HBsAg level tended to be lower in patients achieving HBeAg loss (4.3 vs 4.8 log IU/mL; P = .10). Declines in HBsAg over a period of up to 6 years for HBeAgpositive patients with or without HBeAg loss are depicted in Figure 2B . Patients with HBeAg loss achieved a decline of 2.5 log IU/mL (P = .006, compared with baseline), and patients remaining HBeAg-positive achieved a decline of 1.8 log IU/ mL after 6 years of therapy (P < .001). Five (8%) HBeAg-positive patients achieved HBsAg seroclearance in our study ( Table 2 ). Three of those 5 (60%) also seroconverted, with detectable titers of antibody against HBsAg (anti-HBs). Baseline HBsAg levels were comparable between HBeAg-positive patients who achieved seroclearance of HBsAg and those who remained positive for HBsAg (5.0 vs 4.6 log IU/ mL; P = .46). Individual HBsAg kinetics for patients achieving HBsAg seroclearance are depicted in Figure 3A . A decline in HBsAg of at least 2 log IU/mL at month 6 was highly predictive of HBsAg seroclearance; 71% of these patients achieved HBsAg seroclearance and none of the patients with a decline of <2 log IU/mL. The predicted median time to HBsAg seroclearance for HBeAg-positive patients was 18 years (IQR, 10-28 years), while the time needed to achieve a 1-log decline in HBsAg was 3 years (IQR, 2-5 years).
HBeAg-Negative Patients
Three HBeAg-negative patients (8%) achieved HBsAg seroclearance during TDF therapy lasting up to 6 years, of whom only 1 (33%) seroconverted to anti-HBs. In contrast with HBeAg-positive patients, baseline HBsAg levels were considerably lower HBsAg level, log 10 IU/mL, mean ± SD 4.6 ± 1. than those in patients remaining HBsAg positive (1.0 vs 3.0 log IU/mL; P = .05; Table 2 ). Two HBeAg-negative patients had already very low HBsAg levels at start of therapy and became negative for HBsAg within the first 6 months ( Figure 3B ). The third patient had a baseline HBsAg level of >4 log IU/mL, experienced a fast decline in the HBsAg level within the first year, and became HBsAg negative after 4 years. The predicted median time to HBsAg loss for HBeAg-negative patients was 42 years (IQR, 3-83 years), and 10 years (IQR, 5-16 years) were needed to achieve a decline of 1 log IU/mL.
DISCUSSION
This is the first large study investigating HBsAg kinetics in HIV/HBV-coinfected patients treated with long-term TDF. A significant decline in HBsAg level of 2.2 log IU/mL at year 6 was noted within the HBeAg-positive population, while a minimal decline was observed in HBeAg-negative patients. A correlation between CD4 cell count and decline in HBsAg early during treatment was found. A decline in HBsAg early during treatment was shown to be highly predictive of HBsAg seroclearance, which mainly occurred within the first year of TDF therapy. HIV/HBV coinfection has a worse prognosis than monoinfection with either virus, and the presence of HBV is an important determinant of the prognosis in patients who are receiving HAART [19] [20] . HBsAg positivity is the hallmark of HBV infection, and HBsAg clearance signifies clinical cure. However, this end point is rarely achieved in HBV-monoinfected patients, particularly among those who are HBeAg negative [2, 7, 22] .
We showed that the decline in HBsAg level during the first year was relatively fast, was highly predictive for clearance of HBsAg, and was correlated with CD4 cell count in HBeAgpositive patients early during treatment. These findings underline the importance of immune restoration by HAART for HBV clearance in HIV/HBV-coinfected patients. It could also be argued that HBsAg seroclearance in these patients was mainly a secondary effect of HAART, caused by an increasing CD4 cell count, instead of a direct effect of TDF on viral replication and HBsAg production or excretion.
In addition, our study showed that the vast majority of patients with HBsAg seroclearance achieved this endpoint within the first year of TDF-based therapy. Five HBeAg-positive patients achieved HBsAg seroclearance: all showed a very fast decline in HBsAg level, which was accompanied with a strong increase in CD4 cell count. The kinetics of HBsAg early during treatment were thus shown to be highly predictive for HBsAg seroclearance, which was also described by Wursthorn et al in telbivudine-treated patients with HBV monoinfection [17] . Three HBeAg-negative patients achieved HBsAg seroclearance, which is a rare event in NA-treated HBV-monoinfected patients. Two of these HBeAg-negative patients had already very low baseline HBsAg levels and achieved HBsAg seroclearance quickly after initiation of TDF, indicating that this was possibly already an ongoing event and was probably accelerated by treatment and a consecutive increase in CD4 cell count. All patients achieving HBsAg seroclearance in our study were infected by non-Asian HBV genotypes, an important observation that was also noted in the pivotal entecavir and TDF trials [2, 7] . Genotypic and racial distribution thus seem important to take into account when comparing HBsAg seroclearance rates between studies with (different) NAs, as well as in pegylated interferontreated patients [23] .
Our study showed that the decline in HBsAg was mostly confined to HBeAg-positive HIV/HBV-coinfected patients and tended to be steeper in HBeAg-positive patients who achieved HBeAg loss. Both findings have also been noted in previous studies involving HBV-monoinfected patients, indicating that besides adequate viral suppression, baseline HBeAg status and achievement of HBeAg loss are both of significant importance and influence the probability of HBsAg seroclearance [2, [16] [17] [18] 24] . Of the baseline variables studied, higher baseline HBsAg level was associated with a stronger decline in HBsAg level for up to 6 years of continuous TDF therapy in HBeAg-positive patients. A smaller study involving 33 HIV/ HBV-coinfected patients did not find this relation between HBsAg decline, HBeAg status, and baseline HBsAg level [21] .
A limitation of our study is its retrospective design. However, because TDF was first registered for HIV-infected individuals, our cohort study has a long follow-up period, with a median of >4 years. Moreover, to our knowledge this is the largest study investigating HBsAg kinetics in coinfected patients treated with TDF as part of antiretroviral therapy.
In conclusion, we showed that long-term TDF therapy leads to a significant decline in HBsAg for HBeAg-positive patients and that HBsAg kinetics early during treatment were highly predictive of HBsAg seroclearance. The correlation between CD4 cell count and HBsAg level kinetics during treatment and the high rate of HBsAg seroclearance within the first year underlines the importance of immune restoration in the clearance of HBsAg.
Notes
